Depomed, Inc. Announces Allowance of Additional U.S. Patent Covering Gabapentin GR®

MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. patent application number 10/280,309.